Výsledky vyhledávání

Akademický článek

Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy.

Autor: Gonzales E; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Gardin A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Almes M; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Darmellah-Remil A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France., Seguin H; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France., Mussini C; Pathology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Franchi-Abella S; Pediatric Radiology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Duché M; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Pediatric Radiology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Ackermann O; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Thébaut A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Habes D; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Hermeziu B; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Lapalus M; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Falguières T; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Combal JP; Vivet Therapeutics, Paris, France., Benichou B; Vivet Therapeutics, Paris, France., Valero S; Vivet Therapeutics, Paris, France., Davit-Spraul A; Biochemistry; Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Jacquemin E; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2023 Jul 13; Vol. 5 (10), pp. 100844. Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.

Autor: Weber ND; Vivet Therapeutics S.L., Pamplona, Spain., Odriozola L; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain., Ros-Gañán I; Vivet Therapeutics S.L., Pamplona, Spain., García-Porrero G; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Salas D; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain., Argemi J; Liver Unit, Internal Medicine Department, Clínica Universidad de Navarra and Hepatology Program, CIMA, Universidad de Navarra, Pamplona, Spain.; Division of Medicine, Gastroenterology and Hepatology Department, University of Pittsburgh, Pittsburgh, PA, USA.; Centro de Investigacion Biomedica en Red (CIBER-Ehd), Madrid, Spain., Combal JP; Vivet Therapeutics S.A.S., Paris, France., Kishimoto TK; Selecta Biosciences, Watertown, MA, USA., González-Aseguinolaza G; Vivet Therapeutics S.L., Pamplona, Spain.; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2023 Feb 24; Vol. 5 (5), pp. 100713. Date of Electronic Publication: 2023 Feb 24 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database.

Autor: Daniel-Robin T; Vivet Therapeutics, Paris, France. Electronic address: tdaniel@vivet-therapeutics.com., Bénichou B; Vivet Therapeutics, Paris, France., Leboucher C; Creativ-Ceuticals, Lyon, France., Blein C; Creativ-Ceuticals, Lyon, France., Combal JP; Vivet Therapeutics, Paris, France.

Publikováno v: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2022 Dec; Vol. 46 (10), pp. 101992. Date of Electronic Publication: 2022 Jul 03.

Zobrazit plný text záznamu

Akademický článek

Gene Therapy in Combination with Nitrogen Scavenger Pretreatment Corrects Biochemical and Behavioral Abnormalities of Infant Citrullinemia Type 1 Mice.

Autor: Bazo A; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Lantero A; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Mauleón I; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Neri L; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Poms M; Department of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland., Häberle J; Division of Metabolism, Children's Research Centre (CRC), University Children's Hospital Zurich, 8091 Zurich, Switzerland., Ricobaraza A; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Bénichou B; Vivet Therapeutics, S.A.S., 75008 Paris, France., Combal JP; Vivet Therapeutics, S.A.S., 75008 Paris, France., Gonzalez-Aseguinolaza G; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain.; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Aldabe R; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 29; Vol. 23 (23). Date of Electronic Publication: 2022 Nov 29.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání